Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 362

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 362
---
 to ensure that genetic testing is continuously improved. This is critical in the context of growing demand and mass adoption of these technologies. Likewise, we will focus on making our products increasingly affordable and broadly available. History and Development OmnigenicsAI was created as an artificial intelligence -drivengenomics company that grows through strategic partnerships, acquisitions, and exclusive licenses with the mission of providing secure, precise, and reliable biological data that enables people to live healthier lives. OmnigenicsAI incorporated the intellectual property rights, including trade secrets, of Heritas Argentina, a precision medicine company from Argentina focused on the Latin American market and plans to develop our strategic consortium. Heritas Argentina has been a genomics pioneer in Latin America for over eight years with proprietary developed tests and prevention services, primarily distributed through partnerships. By combining the strengths of our current and future partnerships, we expect to position ourselves as a leading AI -enabledgenomics company. OmnigenicsAI’s expertise spans biological, scientific, technological and market know -how, all of which are critical for product development and execution. Supported by a diverse and specialized team, we are crafting a highly complementary and comprehensive product portfolio that addresses a broad spectrum of health needs. 179 We believe we are pioneering the integration of genomic testing results with clinical and lifestyle data in the region. This combination creates enriched genomic datasets filled with potential insights, which we expect to be disruptive of patient’s healthcare, specially, since there are no data sets built from Latin American genes, a population not only present in the region, but is growing globally as well. OmnigenicsAI expects to commercialize its product portfolio through two brands: (i) Rewell, offering wellness and prevention solutions for consumers, and (ii) Heritas Diagnostics offering precise clinical genetic services for patients and physicians. This portfolio aims to address various aspects of healthcare, targeting the general population through Rewell for preventative measures and secondary care through Heritas for diagnostic services. We currently employ AI by including machine learning models and third party LLMs that routinely assist in data analysis and service delivery, subject to rigorous validation and monitoring. The end -to -enddata we collect from our comprehensive services suite is actively used to train and improve these AI systems, and we are implementing controls and procedures designed to protect sensitive data. Looking ahead, within the next five years we plan to develop more sophisticated AI -poweredtools and complex models that will increasingly provide broader support for health management, clinical research, drug discovery studies and clinical trials while working to meet evolving regulatory requirements and industry